Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Quest Diagnostics Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $23.31, while Quest Diagnostics Inc trades at $204.71 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| CWEB | DGX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $216.02 |
52-Week Low | $17.70 | $166.42 |
Market Cap | — | $22.80B |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $21.61, down 1.46% today, with technical indicators showing a bullish bias from moving averages but a neutral stance from oscillators. The stock lacks recent fundamental data, with key valuation and profitability ratios unavailable. A dividend of $0.09 is scheduled for June 2026, indicating a potential income component.
The outlook is mixed due to incomplete financials; technical strength offers near-term upside potential, but investment decisions require updated earnings and revenue figures. Risks include data gaps and market volatility, warranting caution until fundamental clarity emerges from SEC filings or company announcements.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
